Ursula A. Matulonis, MD, on the Safety of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.

Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, who spoke with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, highlighted the safety profile of mirvetuximab soravtansine (IMGN853) in folate receptor α (FRα)–high platinum-resistant ovarian cancer from the phase 3 SORAYA trial (NCT04296890).

In particular, she stated that no new toxicities were observed. Additionally, although ocular toxicities were notable, Matulonis explained that they weren’t permanent and commonly resolved by the next treatment cycle.

Transcript:

The safety findings were what we have seen already with mirvetuximab soravtansine. We did not see any new safety findings. The toxicities that were seen were mostly low-grade ocular toxicities [and] low-grade gastrointestinal toxicities. We didn’t see any alopecia, [and there was] minimal neuropathy and also minimal hematologic toxicities. It’s important to point out that with the ocular toxicities, about half the patients had some ocular toxicity, and about 60% of them had that toxicity resolve by the next cycle and the remainder either was managed with a dose delay or dose reduction. None of the eye toxicities are permanent; they’re all reversible.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.